Back to Search
Start Over
Advances in non-hormonal pharmacotherapy for the treatment of male infertility: the role of inositols.
- Source :
-
Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2022 Jun; Vol. 23 (9), pp. 1081-1090. Date of Electronic Publication: 2022 Apr 03. - Publication Year :
- 2022
-
Abstract
- Introduction: Several antioxidants are available for the treatment of male infertility. Although the benefit of myo-inositol (MYO) and D-chiro-inositol (DCI) for female infertility is recognized, their role in male infertility is a matter of debate.<br />Areas Covered: The authors review the impact that treatment with MYO and/or DCI may have on conventional and bio-functional sperm parameters [mitochondrial membrane potential (MMP), sperm chromatin compactness, and sperm DNA fragmentation (SDF)], seminal oxidative stress (OS), and pregnancy, miscarriage, and live birth rates, and the possible mechanisms involved. Furthermore, the authors gather evidence on the effects of MYO and/or DCI on sperm function in vitro .<br />Expert Opinion: MYO can improve sperm count, motility, capacitation, acrosome reaction, and MMP. No data are currently available on the effects of DCI in vivo . Both MYO and DCI ameliorate sperm motility and MMP in vitro . Therefore, the use of inositols should be preferred in patients with idiopathic asthenozoospermia, especially in case of impaired sperm mitochondrial function. Due to their insulin-sensitizing action, a role for these molecules may be envisaged for the treatment of infertility caused by carbohydrate metabolism derangement.
Details
- Language :
- English
- ISSN :
- 1744-7666
- Volume :
- 23
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Expert opinion on pharmacotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 35348407
- Full Text :
- https://doi.org/10.1080/14656566.2022.2060076